Alzheimer Disease Clinical Trial
Official title:
Safety and Effects of Cefaly on Mild Cognitive Impairment With Insomnia and Exploration of Structural and Functional Connectivity Changes
This study aims to validate the safety and impact of transdermal trigeminal electrical neuromodulation(Cefaly) on mild cognitive impairment patients with insomnia on brain functional and structural connectivity as well as sleep parameters evidenced by polysomnography and sleep surveys, with consideration for amyloid positivity and brain-derived neurotrophic factor .
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 30, 2023 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility | Inclusion Criteria: - Diagnosed with mild cognitive impairment by modified Peterson's criteria - Identified as amyloid positive by amyloid PET result - Insomnia severity index of more than 15 or diagnosed with insomnia disorder by Diagnostic Statistical Manual-5 Exclusion Criteria: - Subjects with active psychiatric or neurological disorders - Unstable medical conditions (Myocardial infarction, cerebral infarction, congestive heart failures etc.) - Moderate to severe obstructive sleep apnea (apnea hypopnea index of more than 15), rapid eye movement disorder, narcolepsy - On regular hypnotic medication (can enroll if there was 2-week wash out period) - Currently receiving or having a past history of cognitive behavioral therapy for insomnia - Patients who received transcranial magnetic stimulation (TMS), transcranial direct current stimulation, within 2 weeks before enrollment - Who are on cognitive enhancers (choline alfoscerate, acetylcarnitine, acetylcholinesterase inhibitors, NMDA receptor antagonist) - History of cerebral infarction or Parkinson's disease - History of facial or brain trauma - A subject with allergy to acrylic acid - A subject who is sensitive to electrical devices - A subject who are uncooperative to MRI process |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | St.Vincent's Hospital, the Catholic University of Korea | Suwon |
Lead Sponsor | Collaborator |
---|---|
Saint Vincent's Hospital, Korea |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes from Baseline Pittsburgh sleep quality index(PSQI) at 3 months | PSQI global score of more than 5 signifies major sleep disturbance, higher scores suggesting greater sleep disturbance | Post 3-month intervention | |
Primary | Changes from Baseline Insomnia severity index(ISI) at 3 months | ISI is a brief, self-rated scale that is widely used to measure insomnia severity. With seven items scored on a 0-4 scale, it only takes about 5 minutes to complete and scores of 15 or more indicates insomnia of moderate to severe severity | Post 3-month intervention | |
Primary | Changes from Baseline Epworth sleepiness scale(ESS) at 3 months | ESS is a self-administered scale with eight questionnaires measuring sleepiness in daily life. Score of more than 10 signifies clinically meaningful daytime sleepiness, with higher scores indicating more severe sleepiness. | Post-3 month intervention | |
Primary | Changes from Baseline Total time in bed(TIB) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Total sleep time(TST) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Sleep efficiency(SE) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Proportion of stage 1 sleep(N1, %) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Proportion of stage 2 sleep(N2, %) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Proportion of stage 3 sleep(N3, %) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Proportion of REM sleep(R, %) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline REM sleep latency(REML) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Sleep latency(SL) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Apnea-hypopnea index(AHI) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Limb movement index(LMI) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Periodic limb movement index(PLMI) at 3 months | One of polysomnography measures | Post 3-month intervention | |
Primary | Changes from Baseline Cortical thickness changes at 3 months | One of neuroimaging measures | Post 3-month intervention | |
Primary | Changes from Baseline Functional connectivity measure at 3 months | One of neuroimaging measures | Post 3-month intervention | |
Primary | Changes from Baseline Fractional anisotropy at 3 months | One of neuroimaging measures | Post 3-month intervention | |
Primary | Changes from Baseline Mean diffusivity at 3 months | One of neuroimaging measures | Post 3-month intervention | |
Primary | Changes from Baseline Verbal fluency at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention | |
Primary | Changes from Baseline Boston naming test at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention | |
Primary | Changes from Baseline Mini-mental status examination at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention | |
Primary | Changes from Baseline Word list recall at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention | |
Primary | Changes from Baseline Word list recognition at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention | |
Primary | Changes from Baseline Constructional recall at 3 months | One of cognitive measures(subtest of CERAD-K) | Post 3-month intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |